Related Articles for PubMed (Select 17692126)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.

Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J.

Breast Cancer Res. 2007;9(4):R52.

PMID: 17692126 [PubMed - indexed for MEDLINE]

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group.

J Bone Miner Res. 2006 Aug;21(8):1215-23.

PMID: 16869719 [PubMed - indexed for MEDLINE]

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.

Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R.

Ann Oncol. 2004 Feb;15(2):211-7.

PMID: 14760111 [PubMed - indexed for MEDLINE]

Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.

Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R.

Bone. 2007 Jan;40(1):205-10. Epub 2006 Aug 14.

PMID: 16904960 [PubMed - indexed for MEDLINE]

Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.

Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC.

Oncology. 2005;69(6):471-7. Epub 2006 Jan 12.

PMID: 16410685 [PubMed - indexed for MEDLINE]

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group.

Lancet Oncol. 2007 Feb;8(2):119-27.

PMID: 17267326 [PubMed - indexed for MEDLINE]

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R.

Eur J Cancer. 2007 Nov;43(17):2523-31.

PMID: 18029171 [PubMed - indexed for MEDLINE]

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.

Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.

J Clin Oncol. 2006 Aug 1;24(22):3629-35. Epub 2006 Jul 5.

PMID: 16822845 [PubMed - indexed for MEDLINE]

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.

Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.

J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.

PMID: 15983390 [PubMed - indexed for MEDLINE]

10:

Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.

Leder BZ, Finkelstein JS.

Osteoporos Int. 2005 Dec;16(12):1487-94. Epub 2005 Apr 23.

PMID: 15856361 [PubMed - indexed for MEDLINE]

11:

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.

Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE.

J Clin Oncol. 2002 Feb 1;20(3):751-7.

PMID: 11821457 [PubMed - indexed for MEDLINE]

12:

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID: 17610808 [PubMed - indexed for MEDLINE]

13:

Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.

Hutson PR, Love RR, Havighurst TC, Rogers E, Cleary JF.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8722-7.

PMID: 16361559 [PubMed - indexed for MEDLINE]

14:

The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.

Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H.

Breast Cancer Res Treat. 2005 Sep;93(1):61-6.

PMID: 16184460 [PubMed - indexed for MEDLINE]

15:

[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]

de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY.

Bull Cancer. 2004 Dec;91(12):917-27. Review. French.

PMID: 15634633 [PubMed - indexed for MEDLINE]

16:

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.

Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.

PMID: 17618847 [PubMed - indexed for MEDLINE]

17:

Bone safety of aromatase inhibitors versus tamoxifen.

Lønning PE.

Int J Gynecol Cancer. 2006;16 Suppl 2:518-20. Review.

PMID: 17010062 [PubMed - indexed for MEDLINE]

18:

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.

Cancer. 2004 Oct 1;101(7):1482-9. Review.

PMID: 15378476 [PubMed - indexed for MEDLINE]

19:

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID: 17919537 [PubMed - indexed for MEDLINE]

20:

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P, Dowsett M; IMPACT trialists.

Ann Oncol. 2005 Oct;16(10):1632-8. Epub 2005 Jul 19.

PMID: 16030027 [PubMed - indexed for MEDLINE]

Recent Activity